Zurück
www.nasdaq.com/de/symbol/sphs/real-time
Top-News
Sophiris Bio - Reboundkanditat
Beiträge: 99
Zugriffe: 26.864 / Heute: 8
Zugriffe: 26.864 / Heute: 8
|
Werbung
Entdecke die beliebtesten ETFs von Amundi
Lyxor Net Zero 2050 S&P World Climate PAB (DR) UCITS ETF Acc
Perf. 12M: +206,18%
Amundi Nasdaq-100 Daily (2x) Leveraged UCITS ETF - Acc
Perf. 12M: +71,71%
Amundi ETF Leveraged MSCI USA Daily UCITS ETF - EUR (C/D)
Perf. 12M: +52,30%
Amundi Japan TOPIX II UCITS ETF - EUR Hedeged Dist
Perf. 12M: +38,10%
Amundi MSCI India II UCITS ETF - EUR Acc
Perf. 12M: +36,22%
ihr das mit dem Produkt aus der Phase 3 könnte dort die Zulassung kommen nach dem fda Antrag.....
und wann wir dieser Antrag gestellt....
und wann wir dieser Antrag gestellt....
seekingalpha.com/article/...io-far-topsalysins-fda-application
schon länger auf Watch.
Wird 2017 in mein Depot wandern.
Wird 2017 in mein Depot wandern.
www.finanzen.net/analyse/...Bio_Buy-Rodman__Renshaw_LLC_605570
Gelöschter Beitrag.
Einblenden
»
#57 
www.nasdaq.com/de/symbol/sphs/real-time
SPHS
$2.78
*
0.3
12.1%
SPHS
$2.78
*
0.3
12.1%
www.reuters.com/article/...-provides-update-on-to-idUSASA09R1L
seekingalpha.com/article/...ell-positioned-upcoming-catalysts
dann lockt bei positiver News mit der aktuellen MK ein Tenbagger!
Drug Development/Clinical Research
BPH: The company successfully completed a Phase 3 clinical trial for the treatment of the symptoms of BPH. A single treatment with PRX302 (Topsalysin) demonstrated a statistically significant improvement in BPH symptoms over a 12-month period. The drug is designed to be as efficacious as pharmaceuticals, less invasive than surgical intervention, and without the sexual side effects seen with existing treatments.
The company already has a license agreement with Japan for commercialization of Topsalysin.
BPH is a $5 billion market with more than four million patients treated each year in the U.S. alone. The potential market for prostate cancer exceeds $1 billion.
The company is just one trial away from submitting an FDA application and can request the FDA to fast-track their application.
Drug Development/Clinical Research
BPH: The company successfully completed a Phase 3 clinical trial for the treatment of the symptoms of BPH. A single treatment with PRX302 (Topsalysin) demonstrated a statistically significant improvement in BPH symptoms over a 12-month period. The drug is designed to be as efficacious as pharmaceuticals, less invasive than surgical intervention, and without the sexual side effects seen with existing treatments.
The company already has a license agreement with Japan for commercialization of Topsalysin.
BPH is a $5 billion market with more than four million patients treated each year in the U.S. alone. The potential market for prostate cancer exceeds $1 billion.
The company is just one trial away from submitting an FDA application and can request the FDA to fast-track their application.
seekingalpha.com/article/...-digest-spotlighting-sophiris-bio
www.nasdaq.com/de/symbol/sphs/real-time
www.finanzen.net/analyse/Sophiris_Bio_Buy-Maxim_Group_636202
seekingalpha.com/article/...os-upcoming-phase-2b-data-release
www.analystratings.com/articles/...phs-still-has-room-to-grow/
|
Neueste Beiträge aus dem Sophiris Bio Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
2 | 98 | Sophiris Bio - Reboundkanditat | Balu4u | Vassago | 25.04.21 03:04 |
